Nanomaterials, Autophagy, and Lupus Disease.
Fiche publication
Date publication
janvier 2016
Journal
ChemMedChem
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MULLER Sylviane, Dr BIANCO Alberto
Tous les auteurs :
Bianco A, Muller S
Lien Pubmed
Résumé
Nanoscale materials hold great promise in the therapeutic field. In particular, as carriers or vectors, they help bioactive molecules reach their primary targets. Furthermore, by themselves, certain nanomaterials-regarded as protective-can modulate particular metabolic pathways that are deregulated in pathological situations. They can also synergistically improve the effects of a payload drug. These properties are the basis of their appeal. However, nanoscale materials can also have intrinsic properties that limit their use, and this is the case for certain types of nanomaterials that influence autophagy. This property can be beneficial in some pathological settings, but in others, if the autophagic flux is already accelerated, it can be deleterious. This is notably the case for systemic lupus erythematosus (SLE) and other chronic inflammatory diseases, including certain neurological diseases. The nanomaterial-autophagy interaction therefore must be treated with caution for therapeutic molecules and peptides that require vectorization for their administration.
Mots clés
Animals, Anti-Inflammatory Agents, Non-Steroidal, administration & dosage, Autophagy, drug effects, Chronic Disease, Humans, Inflammation, drug therapy, Lupus Erythematosus, Systemic, drug therapy, Nanostructures, administration & dosage, Peptides, administration & dosage
Référence
ChemMedChem. 2016 Jan;11(2):166-74